Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting
Authors:
- On behalf of the Rheumatology Italian Study GroupOGOn behalf of the Rheumatology Italian Study Group
- Giovanna FerraraGFGiovanna Ferrara
- Greta MastrangeloGMGreta Mastrangelo
- Patrizia BaronePBPatrizia Barone
- Francesco La TorreFrancesco La Torre
- Silvana MartinoSMSilvana Martino
- Giovanni PappagalloGPGiovanni Pappagallo
- Angelo RavelliAngelo Ravelli
- Andrea TaddioATAndrea Taddio
- Francesco ZulianFZFrancesco Zulian
- Rolando CimazRCRolando Cimaz
Open Access
- 11 July 2018
- journal article
- review article
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 16 (1) , 1-14
Abstract
Conventional pharmacological therapies for the treatment of juvenile idiopathic arthritis (JIA) consist of non-biological, disease-modifying antirheumatic drugs, among which methotrexate (MTX) is the most commonly prescribed. However, there is a lack of consensus-based clinical and therapeutic recommendations for the use of MTX in the management of patients with JIA. Therefore, the Methotrexate Advice and RecommendAtions on Juvenile Idiopathic Arthritis (MARAJIA) Expert Meeting was convened to develop evidence-based recommendations for the use of MTX in the treatment of JIA. The preliminary executive committee identified a total of 9 key clinical issues according to the population, intervention, comparator, outcome (PICO) approach, and performed an evidence-based, systematic, literature review. During the subsequent Expert Meeting, the relevant evidence was assessed and graded, and 10 recommendations were made. Recommendations relating to the efficacy, optimal dosing and route of administration and duration of treatment with MTX in JIA, and to the issue of folic acid supplementation to prevent MTX side effects, use of MTX in the treatment of chronic JIA-associated uveitis, combination treatment with biologic agents, and the use of vaccinations in patients with JIA were developed. The selected topics were considered to represent clinically important issues facing clinicians caring for patients with JIA. Evidence was insufficient to formulate recommendations for the use of biomarkers predictive of treatment response. These consensus recommendations provide balanced and evidence-based recommendations designed to have broad value for physicians and healthcare clinicians involved in the clinical management of patients with JIA.Keywords
This publication has 116 references indexed in Scilit:
- Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvementArthritis Research & Therapy, 2012
- Effective seroconversion and safety following the pandemic influenza vaccination (anti-H1N1) in patients with juvenile idiopathic arthritisScandinavian Journal of Rheumatology, 2012
- Association of the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritisAnnals of the Rheumatic Diseases, 2011
- 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic featuresArthritis Care & Research, 2011
- Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature researchAnnals of the Rheumatic Diseases, 2009
- Identification of a novel susceptibility locus for juvenile idiopathic arthritis by genome‐wide association analysisArthritis & Rheumatism, 2008
- Primary Vaccine Failure after 1 Dose of Varicella Vaccine in Healthy ChildrenThe Journal of Infectious Diseases, 2008
- Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritisAnnals of the Rheumatic Diseases, 2007
- Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritisThe Journal of Pediatrics, 1996
- Liver biopsy findings in patients with juvenile rheumatoid arthritis receiving long-term, weekly methotrexate therapyThe Journal of Pediatrics, 1996